# Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation

> **NCT02957552** · PHASE1 · UNKNOWN · sponsor: **University Hospital Tuebingen** · enrollment: 7 (estimated)

## Conditions studied

- Pediatric Liver Transplantation

## Interventions

- **BIOLOGICAL:** Mesenchymal Stem Cells

## Key facts

- **NCT ID:** NCT02957552
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-03-10
- **Primary completion:** 2019-12
- **Final completion:** 2021-12
- **Target enrollment:** 7 (ESTIMATED)
- **Last updated:** 2018-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02957552

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02957552, "Safety and Tolerance of Immunomodulating Therapy With Donor-specific MSC in Pediatric Living-Donor Liver Transplantation". Retrieved via AI Analytics 2026-07-07 from https://api.ai-analytics.org/clinical/NCT02957552. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*